Breaking Finance News

N+1 Singer reported on Vernalis PLC (LON:VER), keeping its stock price target at 46.00GBX earlier today

N+1 Singer hold steady the price target of Vernalis PLC (LON:VER) at 46.00GBX reporting a possible upside of 0.13%.

On 9/22/2016, Panmure Gordon released a statement about Vernalis PLC (LON:VER) maintained the target price at 76.00GBX that suggested an upside of 0.71%.

Having a price of 40.88GBX, Vernalis PLC (LON:VER) traded -8.15% lower on the day. With the last stock price down -10.70% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. VER has recorded a 50-day average of 43.85GBX and a two hundred day average of 45.78GBX. Trade Volume was up over the average, with 308,767 shares of VER changing hands over the typical 293,413

Recent Performance Chart

Vernalis PLC (LON:VER)

Vernalis PLC has with a one year low of 31.00GBX and a one year high of 79.00GBX and has a market capitalization of 0 GBX.

A total of 5 brokerages have issued a ratings update on Vernalis PLC. Two brokerages rating the company a strong buy, two brokerages rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of 83.60GBX.

General Company Details For Vernalis PLC (LON:VER)

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine. The Company also has four prescription cough cold products under development, and a pipeline of research and new chemical entity (NCE) development programs. Its commercial pipeline candidates include CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. The Company is also engaged in fragment- and structure-based drug discovery. It has two development products in the central nervous system (CNS) therapeutic area: the fatty acid amide hydrolase (FAAH) inhibitor V158866 for pain, and V81444, an adenosine A2A receptor antagonist as a treatment for CNS diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *